Skip to main content

Table 1 Study cohort characteristics according to past Metformin usage

From: Past use of metformin is associated with increased risk of myelodysplastic syndrome development in diabetes mellitus patients: a cross-sectional study of 54,869 patients

Variable

All patients

[n = 54,869]

non-Metformin

[n = 34,551]

Metformin

[n = 20,318]

P-value

Male gender; N (%)

32,747 (59.7)

21,061 (61)

11,686 (57.5)

< 0.001

Age*; years (median [IQR])

71 [62, 79]

71 [62, 79]

70 [62, 78]

< 0.001

MDS; N (%)

287 (0.5)

154 (0.4)

133 (0.7)

0.001

CHF; N (%)

9,837 (17.9)

6,338 (18.3)

3,499 (17.2)

0.001

CKD; N (%)

3,428 (6.2)

3,074 (8.9)

354 (1.7)

< 0.001

Dementia; N (%)

2,114 (3.9)

1,496 (4.3)

618 (3)

< 0.001

Hypertension; N (%)

33,162 (60.4)

21,260 (61.5)

11,902 (58.6)

< 0.001

  1. MDS = myelodysplastic syndrome; CHF = congestive heart failure; CKD = chronic kidney disease
  2. *Age at first hospitalization